louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01707875: Fetal Brain Asymmetry: in Utero and Early Neonatal Follow up
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Fetal Ventricle Brain Asymmetry
Lead sponsor: HaEmek Medical Center, Israel
Sponsor class: OTHER
First posted: 2012-10-16
Enrollment: 6
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 42
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pregnant women with fetal ventricle brain asymmetry

Brief summary: Fetal brain asymmetry is considered a normal developmental processes. The size and shape of the lateral ventricles are interdependence with the brain parenchyma. Abnormal development of the fetal brain may cause unilateral or bilateral ventriculomegaly. Fetal cerebral ventricle measurement is one of the most frequently used sonographic tool for the evaluation of brain development. It is easier to evaluate and measure the distal cerebral ventricle, and therefore data concerning the normal range of asymmetry and the normal progress of the asymmetry are limited.

The objective of the study is to follow up the incidental finding of fetal ventricle brain asymmetry between 19-30 weeks of pregnancy.


Eligibility criteria: Inclusion Criteria:

* 18-42 years old pregnant women
* 19-30 weeks of pregnancy
* No medical history of chronic disease
* No medical history of drug therapy
* No other findings on ultrasound examination
* Low risk pregnancy

Exclusion Criteria:

* Fetal malformation
* Chronic maternal disease
* Fetal chromosomal aberration
* suspected fetal infection

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT07002775: Which Position Is Better For CPR In OHCA Patients?
Official title: Use Transesophageal Echocardiography Comparing Head Up And Supine Cardiopulmonary Resuscitation On Cerebral And Systemic Hemodynamics In OHCA Patients
Study type: INTERVENTIONAL
Overall status: ENROLLING_BY_INVITATION
Phase: NA
Conditions: Cardiac Arrest (CA)
Keywords: OHCA
TEE
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
Collaborators: name: Chang Bing Show Chwan Memorial Hospital
First posted: 2025-06-04
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Use Transesophageal ultrasound in OHCA patients to identify the proper CPR position


Eligibility criteria: Inclusion Criteria:

* Out of hospital cardiac arrest patients

Exclusion Criteria:

* DNR was signed,
* Age under 18
* Trauma patients
* Patients hard to establish advanced airway
* C spine injury patients

Primary outcomes:
measure: cardiac output
timeFrame: check cardiac output while CPR(Periprocedural)(after TEE insertion) in head up and supine position
measure: stroke volume
timeFrame: check stroke volume while CPR(Periprocedural)(after TEE insertion) in head up and supine position
Secondary outcomes:
Other outcomes:
Locations:
city: Changhua
country: Taiwan
facility: Chang Bing Show Chawan Memorial Hospital
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Taiwan University Hospital
name: WANCHING LIEN
role: STUDY_DIRECTOR
References:
citation: Moore JC, Salverda B, Lick M, Rojas-Salvador C, Segal N, Debaty G, Lurie KG. Controlled progressive elevation rather than an optimal angle maximizes cerebral perfusion pressure during head up CPR in a swine model of cardiac arrest. Resuscitation. 2020 May;150:23-28. doi: 10.1016/j.resuscitation.2020.02.023. Epub 2020 Feb 27.
citation: Moore JC, Holley J, Segal N, Lick MC, Labarere J, Frascone RJ, Dodd KW, Robinson AE, Lick C, Klein L, Ashton A, McArthur A, Tsangaris A, Makaretz A, Makaretz M, Debaty G, Pepe PE, Lurie KG. Consistent head up cardiopulmonary resuscitation haemodynamics are observed across porcine and human cadaver translational models. Resuscitation. 2018 Nov;132:133-139. doi: 10.1016/j.resuscitation.2018.04.009. Epub 2018 Apr 24.
citation: Kim T, Shin SD, Song KJ, Park YJ, Ryu HH, Debaty G, Lurie K, Hong KJ. The effect of resuscitation position on cerebral and coronary perfusion pressure during mechanical cardiopulmonary resuscitation in porcine cardiac arrest model. Resuscitation. 2017 Apr;113:101-107. doi: 10.1016/j.resuscitation.2017.02.008. Epub 2017 Feb 16.
citation: Debaty G, Shin SD, Metzger A, Kim T, Ryu HH, Rees J, McKnite S, Matsuura T, Lick M, Yannopoulos D, Lurie K. Tilting for perfusion: head-up position during cardiopulmonary resuscitation improves brain flow in a porcine model of cardiac arrest. Resuscitation. 2015 Feb;87:38-43. doi: 10.1016/j.resuscitation.2014.11.019. Epub 2014 Nov 28.
Clinical trial NCT05310175: Efficacy of Acupuncture at Acupoints Group Around the Base of Skull for Post-Stroke Depression
Official title: Efficacy of Acupuncture at Acupoints Group Around the Base of Skull for Post-Stroke Depression: a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Post-stroke Depression
Lead sponsor: China Academy of Chinese Medical Sciences
Sponsor class: OTHER
First posted: 2022-04-04
Enrollment: 98
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this trial is to evaluate the efficacy and safety of electroacupuncture at acupoints group around the base of skull for post-stroke depression.

Detailed description: 98 eligible participants with post-stroke depression will be recruited and randomly assigned to the experimental group and the control group in a ratio of 1:1. Participants in both groups will receive electroacupuncture or placebo acupuncture treatment at acupoints group around the base of skull 3 times a week for 4 weeks, and followed up for 24 weeks.

Eligibility criteria: Inclusion Criteria:

1. Conforming to the criteria for the diagnosis of PSD recommended by the "Chinese Expert Consensus on Clinical Practice of Post-Stroke Depression";
2. Aged 40 to 80 years old;
3. The score of HDRS-24 item scale is more than 8 points and less than 35 points, that is, mild to moderate depression;
4. Has not received antidepressant treatment or has been discontinued for more than 2 weeks before entering treatment, and has not participated in other ongoing clinical trials.

Exclusion Criteria:

1. Subjects with history of mental illness or family history of mental illness;
2. Subjects with severe heart, liver, kidney, hematopoietic system, endocrine and immune system diseases;
3. Subjects with dementia, aphasia, cognitive dysfunction or unable to cooperate with examination and treatment;
4. Subjects installed with the cardiac pacemaker;
5. Pregnant or lactating patients.

Primary outcomes:
measure: The change rate of the total score of Hamilton Depression Rating Scale
timeFrame: Baseline, week 4
Secondary outcomes:
measure: Changes in the scores of HDRS and its seven kinds of factors
timeFrame: Baseline, week4, week16 and week28
measure: Change in the scores of Beck Depression Inventory (BDI)
timeFrame: Baseline, week4, week16 and week28
measure: Change in the scores of National Institute of Health stroke scale (NIHSS)
timeFrame: Baseline, week4, week16 and week28
measure: Change in the scores of Barthel Index (BI)
timeFrame: Baseline, week4, week16 and week28
Other outcomes:
Locations:
city: Beijing
country: China
facility: China Academy of Chinese Medical Sciences
Study officials:
affiliation: China Academy of Chinese Medical Sciences
name: Yuxiao Zeng
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00202475: Collection of Autologous Blood Products by Double Erythrocytapheresis
Official title: Collection of Autologous Blood Products by Double Erythrocytapheresis - Cost Effectiveness Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Pre Operative Autologous Donation
Keywords: Dubble eerythrocytapheresis
Lead sponsor: Sanquin Research & Blood Bank Divisions
Sponsor class: OTHER
Collaborators: name: Atrium Medical Center
name: Maasland Hospital
First posted: 2005-09-20
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The project will determine the advantages of double erythrocytapheresis in the collection of preoperative autologous erythrocytes as compared to the standard collections of whole blood. The study will assess the total reduction in the number of procedures required to obtain the preoperative units ordered by the surgeon. Also, successfulness of erythrocytaphereses versus classical whole blood collection for these patients will be compared.

Detailed description: The project will determine the advantages of double erythrocytapheresis in the collection of preoperative autologous erythrocytes as compared to the standard collections of whole blood. The study will assess the total reduction in the number of procedures required to obtain the preoperative units ordered by the surgeon. Also, successfulness of erythrocytaphereses versus classical whole blood collection for these patients will be compared.

Eligibility criteria: Inclusion Criteria:

* Elective surgery

Exclusion Criteria:

* Malignancies
* Severe arrhythmias
* Congestive heart failure
* Recent angina
* Epileptic seizures in the last 3 months before collection

Primary outcomes:
measure: decline in Hemoglobine levels
timeFrame: surgery
Secondary outcomes:
measure: Storage parameters- ATP
timeFrame: 35 days
Other outcomes:
Locations:
city: Maastricht
country: Netherlands
facility: Sanquin Bloodbank
state: Limburg
city: Maastricht
country: Netherlands
facility: Sanquin Blood Bank Southeast Region
Study officials:
affiliation: Sanquin Research and Blood Bank Divisions
name: Eva Rombout, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00002275: A Comparison of Two Types of Injected Nutritional Supplements in Patients With AIDS and Pneumocystis Carinii Pneumonia (PCP)
Official title: Lipid-Based Parenteral Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome and Pneumocystis Carinii Pneumonia. A Comparison of Two Lipid Formulations
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV Infections
Keywords: Weight Loss
Pneumonia, Pneumocystis carinii
Parenteral Nutrition
Liposyn
Acquired Immunodeficiency Syndrome
Lead sponsor: Abbott
Sponsor class: INDUSTRY
First posted: 2001-08-31
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The objectives of this study are:

To establish whether there is a difference in clinical effectiveness of Liposyn II 20 percent as compared with Liposyn III 2 percent in AIDS patients with Pneumocystis carinii pneumonia (PCP). To compare the effects of the two lipid emulsions on immunologic function in AIDS patients. To compare the effect of the two lipid emulsions on HIV load in AIDS patients as measured by reverse transcriptase (RT) in culture. To determine whether a decrease in HIV infectivity is greater in patients given a parenteral feeding regimen containing Liposyn II 20 percent or Liposyn III 2 percent.


Eligibility criteria: Inclusion Criteria

Concurrent Medication:

Allowed:

* All drugs used for the standard treatment of Pneumocystis carinii pneumonia (PCP).
* Other drugs for treatment of other AIDS conditions if they have been started more than 3 months prior to study entry.

Patients must have:

* Diagnosis of AIDS.
* Weight loss \> 10 percent of premorbid body weight.
* First or second episode of acute Pneumocystis carinii pneumonia (PCP).

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

* Do Not Resuscitate (DNR) status.
* Biliary stasis.

Patients with the following are excluded:

* Do Not Resuscitate (DNR) status.
* Biliary stasis.

Prior Medication:

Excluded within 3 months of study entry:

* Immunomodulators.
* Antiviral new DT

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: East Orange
country: United States
facility: East Orange Veterans Administration Med Ctr
state: New Jersey
Study officials:
References:
citation: Martin DF, Parks DJ, Mellow SD, Ferris FL, Walton RC, Remaley NA, Chew EY, Ashton P, Davis MD, Nussenblatt RB. Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial. Arch Ophthalmol. 1994 Dec;112(12):1531-9. doi: 10.1001/archopht.1994.01090240037023.
Clinical trial NCT00450775: Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars
Official title: Evaluation of the Efficacy, Tolerability, and Patient Acceptance of Dermatix Q for the Prevention and Management of Scars
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Scars
Lead sponsor: Innovative Medical
Sponsor class: INDUSTRY
First posted: 2007-03-22
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to evaluate the efficacy and patient acceptance of Dermatix Q for the prevention and treatment of scarring.


Eligibility criteria: Inclusion Criteria:

* Female or male patients at least 18 years of age
* Patients who are at serious risk of hypertrophic scarring (due to family history, race, recent surgery, etc)
* Able and willing to provide informed consent and likely to complete all study visits
* All Fitzpatrick skin types will be evaluated

Exclusion Criteria:

* Known contraindications to Dermatix or any of its components
* Age of scar is \> 4 months
* Keloid scars (scars with increased fibroblastic activity that has exceeded the boundaries of the original scar)

Primary outcomes:
measure: efficacy
timeFrame: 1 yr
Secondary outcomes:
measure: patient acceptance
timeFrame: 1 yr
Other outcomes:
Locations:
city: Coral Gables
country: United States
facility: Dadeland Dermatology
state: Florida
Study officials:
affiliation: Dadeland Dermatology
name: David Rodriguez, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01092975: Safety of Phenylephrine for Oral Mucositis Prevention
Official title: A Phase I Safety Study of Phenylephrine Applied Topically to the Oral Mucosa in Cancer Patients Receiving Radiation to Sub-mandibular Lymph Nodes
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Mucositis
Stomatitis
Keywords: radiotherapy
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
First posted: 2010-03-25
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to determine if applying the drug phenylephrine to the inside of the mouth can be done safely and is tolerable to use in cancer patients receiving radiation to the Sub-mandibular lymph nodes.


Eligibility criteria: Inclusion Criteria:

* cancer patients scheduled to receive at least 5 weeks of radiation therapy to the sub-mandibular lymph nodes
* normal ECG
* normal blood pressure

Exclusion Criteria:

* untreated cardiac disease
* connective tissue disorders
* open sores, wound, ulcerations to oral cavity
* allergy to phenylephrine
* know untreated hypertensin
* abnormal ECG in past 6 months
* taking prescription monoamine oxidase inhibitor (MAOI)
* are pregnant

Primary outcomes:
measure: Safety: the presence or absence of mucosal or systemic toxicity related the the topical application of phenylephrine.
timeFrame: 24 months
Secondary outcomes:
measure: Efficacy: the the mucositis severity area-under-the-curve (AUC) where the severity of oral mucositis on each treatment day will be scored, summed, and plotted graphically.
timeFrame: 24 months
Other outcomes:
Locations:
city: Madison
country: United States
facility: University of Wisconsin Carbone Cancer Center
state: Wisconsin
Study officials:
affiliation: University of Wisconsin, Madison
name: James F Cleary, MBBS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03980275: Selective Laryngeal Reinnervation for Bilateral Vocal Fold Paralysis
Official title: Selective Laryngeal Reinnervation for Bilateral Vocal Fold Paralysis
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Bilateral Vocal Cord Paralysis
Keywords: Bilateral vocal fold paralysis
Tracheostomy dependency
Glottic airway obstruction
Stridor
Lead sponsor: Weill Medical College of Cornell University
Sponsor class: OTHER
First posted: 2019-06-10
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients with bilateral vocal fold paralysis

Brief summary: This is a prospective observational study examining the treatment outcomes of selective laryngeal reinnervation procedures for patients with bilateral vocal fold paralysis.


Eligibility criteria: Inclusion Criteria:

* Patients aged 18-70
* Patients with bilateral vocal fold paralysis without any improvement for 6 months

Exclusion Criteria:

* Patients with neck or chest radiation
* Patients with severe respiratory compromise
* Patients with cricoarytenoid ankylosis
* Patients with pacemakers
* Patients who are pregnant
* Patients with cochlear implant, or any nerve stimulator implants

Primary outcomes:
measure: Change in breathing function is being assessed and measured by the Dyspnea Index (DI)
timeFrame: Pre-surgery and then post-surgery at 1 week, 1 month, 3 months and every 3 months thereafter up to 18 months, then at 24 months
measure: Change in breathing function is being assessed and measured by pulmonary function testing
timeFrame: Pre-surgery and then post-surgery at 1 week, 1 month, 3 months and every 3 months thereafter up to 18 months, then at 24 months
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Sean Parker Institute for the Voice
state: New York
Study officials:
affiliation: Weill Medical College of Cornell University
name: Babak Sadoughi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05936775: Assessment of Osseointegration Properties of Nano-Hydroxy Apatite Coated Titanium Implant
Official title: Assessment of Osseointegration Properties of Nano-Hydroxy Apatite Coated Titanium Implant Versus Sandblasted Large Thread Acid Etched Implants in Posterior Maxilla. A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Implant Site Reaction
Lead sponsor: October University for Modern Sciences and Arts
Sponsor class: OTHER
First posted: 2023-07-10
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: the purpose of this trial is to evaluate the osseointegration properties of nano-hydroxy apatite coated titanium implants in posterior maxilla. 30 patients will be included in this trial divided into two groups, control and intervention. Primary and secondary implant stability will be measured


Eligibility criteria: Inclusion Criteria:

1. Patients with missing at least one maxillary posterior tooth
2. Patients free from any systemic disease
3. Patients who approve to be included in the trial and sign the informed consent
4. Patients with no intra-bony defect.
5. Adults aged 18 years old and above

Exclusion Criteria:

1. Patients who are allergic to titanium
2. Heavy smoker patient
3. Patients receiving chemotherapy or radiotherapy
4. Patients who refused to be included in the trial

Primary outcomes:
measure: Implant stability
timeFrame: immediately post-operative
measure: Implant stability
timeFrame: 4 weeks post-operative
measure: Implant stability
timeFrame: 6 weeks post-operative
measure: Implant stability
timeFrame: 12 weeks post-operative
Secondary outcomes:
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: October University for Modern Sciences and Arts faulty of Dentistry
Study officials:
affiliation: october university for modern science and arts faculty of dentistry
name: Mohamed H Mahmoud, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02331875: Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity
Official title: Open Label Single Arm Phase Ib-II Study of Pre-operative IPH2201 in Patients With Locally Advanced Resectable Squamous Cell Carcinoma of the Oral Cavity
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Squamous Cell Carcinoma of the Oral Cavity
Lead sponsor: Innate Pharma
Sponsor class: INDUSTRY
First posted: 2015-01-06
Enrollment: 3
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective of this open label Phase Ib/II trial is to evaluate the clinical and pharmacological activity of IPH2201 as a single-agent in treatment-naïve pre-operative patients with operable Squamous Cell Carcinoma of the Oral Cavity .

43 patients are planned to be enrolled. The first 6 patients will receive IPH2201 at a dose of 4 mg/kg q2w x 4. Subsequent patients will be treated at a dose of 10 mg/kg q2w x 4. Standard loco-regional treatment with surgery followed by adjuvant therapy will be initiated after the last administration of IPH2201.


Eligibility criteria: Inclusion criteria:

* Histologically confirmed, primary, previously untreated, resectable squamous cell carcinoma of the oral cavity considered clinically and radiologically as intermediate or high risk, classified II ( with large (≥ 3 cm and ≤ 4cm) cT2cN0cM0 tumors or any cT2cN0cM0 tumor invading neighboring structures) III or IVa according to the American Joint Committee on Cancer
* Adequate liver and renal function

Exclusion criteria:

* Other malignancy
* Abnormal cardiac status
* Autoimmune disease
* Serious concurrent uncontrolled medical disorder
* Systemic treatment with corticosteroids or other immunosuppressive agents within 30 days prior to IPH2201 first administration.

Primary outcomes:
measure: best objective response rate
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Charité University Medicine Berlin
city: L'Hospitalet de Llobregat Barcelona
country: Spain
facility: Instituto Catalan de Oncologia - L'Hospitalet
city: Madrid
country: Spain
facility: Hospital Universitario La Paz
Study officials:
References: